Oleg Nodelman is a member of Aktis Oncology’s Board of Directors. He is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With 20 years of experience in biotech investing, Oleg has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Oleg was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to the biotechnology sector. He currently serves as a Board Member for three publicly traded companies: Prothena (NASDAQ: PRTA), a clinical-stage neuroscience company, AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, and Nuvation Bio (NYSE: NUVB), a clinical stage biopharmaceutical company tackling unmet needs in oncology. Oleg has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.